Notice NOT-HG-22-028 from the NIH Guide for Grants and Contracts

Adapts bioinformatics tools, visualization packages, and annotation resources for research projects to independently and accurately perform research analysis,…
From Medical College of Wisconsin - Mon, 27 Jun 2022 09:07:38 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-AI-22-050 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support computational dynamic modeling of molecular complexes regulating the HIV life cycle, immune responses, and therapeutic interventions in HIV/AIDS using existing and new HIV and HIV/host cell structural datasets.

Funding Opportunity PAR-22-208 from the NIH Guide for Grants and Contracts. The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2019 update to the National Plan to Address Alzheimer's Disease.

Negotiable: Oxford Nanopore Technologies: We are looking for a highly motivated individual to join our Machine Learning Research team as a Scientific Data Analyst / Algorithms Researcher. Oxford, England

The Senior Data Scientist will be involved in Research and Development projects serving as a lead and subject matter expert in the analysis of Gregor’s high…
From Gregor Diagnostics - Sat, 25 Jun 2022 10:08:12 GMT - View all Madison, WI jobs

Familiarity with bioinformatic analysis or RNA-seq data,and CRISPR targeting and sequencing analysis is strongly encouraged. $45,775 a year
From University of Wisconsin–Madison - Sat, 25 Jun 2022 00:57:55 GMT - View all Madison, WI jobs

Funding Opportunity RFA-DA-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to develop psychoplastogenic compounds and related models for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.

Notice NOT-TW-22-003 from the NIH Guide for Grants and Contracts

You are focused on results, a self-starter, able to put the customer first, and team first, and have demonstrated success in using data science to develop and…
From Change Healthcare - Fri, 24 Jun 2022 07:17:09 GMT - View all Wyoming jobs

You are focused on results, a self-starter, able to put the customer first, and team first, and have demonstrated success in using data science to develop and…
From Change Healthcare - Fri, 24 Jun 2022 07:17:07 GMT - View all West Virginia jobs

Notice NOT-OD-22-158 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-023 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-024 from the NIH Guide for Grants and Contracts

Competitive Salary: F. Hoffmann-La Roche AG: The Bioinformatics Senior Research Associate is responsible for designing and troubleshooting PCR-based assays for use with the GenMark Dx ePlex platf Carlsbad, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: Impact HealthcareRoche Sequencing is developing ground-breaking next-generation sequencing products that allow scientists/clinicians powerful new aven Santa Clara, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: We are seeking a talented and highly motivated Principal Bioinformatics Scientist to support development of Roche Diagnostics Molecular Assays that wi Washington D.C. (US)

Competitive Salary: F. Hoffmann-La Roche AG: This position may be based out of Santa Clara, California, USA, with remote work locations possible in The United States.Impact HealthcareRoche Sequen Santa Clara, California (US)

Funding Opportunity PAR-22-174 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

Funding Opportunity PAR-22-173 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.